TY - JOUR
T1 - Viral Hepatitis and Diabetes
T2 - Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination
AU - Karnchanasorn, Rudruidee
AU - Ou, Horng Yih
AU - Lin, James
AU - Chuang, Lee Ming
AU - Chiu, Ken C.
N1 - Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Viral hepatitis has been posited to play a role in the development of type 2 diabetes. Thus, prevention of viral hepatitis through vaccination has the potential to reduce the burden of type 2 diabetes. We have shown that successful hepatitis B vaccination reduces the risk of diabetes by 33 %. Although diabetes can be prevented by behavior modification and pharmaceutical agents, these require significant personal commitment and cost. In contrast, diabetes prevention through hepatitis B vaccination would require little personal commitment and relatively low cost. In this review, we discuss hepatitis viruses A, B, and C and their interaction with diabetes; explore the potential underlying mechanisms and potential for hepatitis vaccination to reduce diabetes; and estimate the medical expense savings that would result from such an intervention. Given the projected increase of diabetes prevalence in the developing regions, where hepatitis B is endemic, exploration of such an intervention is very timely.
AB - Viral hepatitis has been posited to play a role in the development of type 2 diabetes. Thus, prevention of viral hepatitis through vaccination has the potential to reduce the burden of type 2 diabetes. We have shown that successful hepatitis B vaccination reduces the risk of diabetes by 33 %. Although diabetes can be prevented by behavior modification and pharmaceutical agents, these require significant personal commitment and cost. In contrast, diabetes prevention through hepatitis B vaccination would require little personal commitment and relatively low cost. In this review, we discuss hepatitis viruses A, B, and C and their interaction with diabetes; explore the potential underlying mechanisms and potential for hepatitis vaccination to reduce diabetes; and estimate the medical expense savings that would result from such an intervention. Given the projected increase of diabetes prevalence in the developing regions, where hepatitis B is endemic, exploration of such an intervention is very timely.
UR - http://www.scopus.com/inward/record.url?scp=84987819614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84987819614&partnerID=8YFLogxK
U2 - 10.1007/s11892-016-0790-y
DO - 10.1007/s11892-016-0790-y
M3 - Review article
C2 - 27620495
AN - SCOPUS:84987819614
SN - 1534-4827
VL - 16
JO - Current Diabetes Reports
JF - Current Diabetes Reports
IS - 10
M1 - 101
ER -
